NASDAQ:VERV

Verve Therapeutics (VERV) Stock Forecast, Price & News

$13.26

+0.30 (+2.31%)

(As of 09/29/2023 ET)

Compare

Today's Range: $12.79
▼
$13.47
50-Day Range: $11.42
▼
$20.74
52-Week Range: $11.25
▼
$40.88

Volume: 985,181 shs
Average Volume: 718,416 shs
Market Capitalization: $844.93 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $30.83

Verve Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 132.5% Upside
$30.83 Price Target
Short Interest: Bearish
27.86% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.45
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($3.50) to ($3.62) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.67 out of 5 stars

Medical Sector

869th out of 972 stocks

Pharmaceutical Preparations Industry

413th out of 454 stocks

3.3

Analyst's Opinion

Consensus Rating
Verve Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 5 buy ratings, 2 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $30.83, Verve Therapeutics has a forecasted upside of 132.5% from its current price of $13.26.
Amount of Analyst Coverage
Verve Therapeutics has only been the subject of 4 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
27.86% of the float of Verve Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Verve Therapeutics has a short interest ratio ("days to cover") of 19.4, which indicates bearish sentiment.
Change versus previous month
Short interest in Verve Therapeutics has recently increased by 0.17%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Verve Therapeutics does not currently pay a dividend.
Dividend Growth
Verve Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VERV.

1.9

News and Social Media Coverage

News Sentiment
Verve Therapeutics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Verve Therapeutics this week, compared to 2 articles on an average week.
Search Interest
Only 2 people have searched for VERV on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Verve Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Verve Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
21.40% of the stock of Verve Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
97.11% of the stock of Verve Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Verve Therapeutics are expected to decrease in the coming year, from ($3.50) to ($3.62) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Verve Therapeutics is -4.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Verve Therapeutics is -4.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Verve Therapeutics has a P/B Ratio of 1.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Verve Therapeutics (NASDAQ:VERV) Stock

Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

VERV Price History

30 days | 90 days | 365 days | Advanced Chart

VERV Stock News Headlines

September 30, 2023 | americanbankingnews.com

Verve Therapeutics, Inc. (NASDAQ:VERV) Given Consensus Recommendation of "Moderate Buy" by Analysts

September 27, 2023 | finance.yahoo.com

Verve Therapeutics (VERV) Soars 13.8%: Is Further Upside Left in the Stock?

October 1, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Missile" to Replace Nuclear Missiles

CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!

September 26, 2023 | finance.yahoo.com

Verve to Present Interim Data from the heart-1 Phase 1b Clinical Trial of VERVE-101 in HeFH Patients at the American Heart Association’s Scientific Sessions 2023

September 25, 2023 | msn.com

Verve's New Beat: CMO Onboard, Catalysts Ahead, But We're Dancing Solo For Now

September 21, 2023 | finance.yahoo.com

Verve Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

September 18, 2023 | msn.com

Verve names Frederick T. Fiedorek as Chief Medical Officer

September 18, 2023 | markets.businessinsider.com

Verve Therapeutics Names Frederick Fiedorek CMO

October 1, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Missile" to Replace Nuclear Missiles

CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!

September 18, 2023 | finance.yahoo.com

Verve Expands Leadership Team with Appointment of Frederick T. Fiedorek, M.D., as Chief Medical Officer

September 14, 2023 | msn.com

Cantor Fitzgerald Reiterates Verve Therapeutics (VERV) Neutral Recommendation

September 11, 2023 | seekingalpha.com

Cracking The Cholesterol Code: Verve's High-Stakes Bet

August 31, 2023 | finance.yahoo.com

1 Cathie Wood Stock That Could Go Parabolic Soon

August 30, 2023 | markets.businessinsider.com

Cantor Fitzgerald Keeps Their Hold Rating on Verve Therapeutics (VERV)

August 29, 2023 | markets.businessinsider.com

Expert Ratings for Verve Therapeutics

August 18, 2023 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Replimune Group (REPL) and Verve Therapeutics (VERV)

August 15, 2023 | msn.com

Guggenheim Maintains Verve Therapeutics (VERV) Buy Recommendation

August 14, 2023 | seekingalpha.com

Verve Therapeutics, Inc. 2023 Q2 - Results - Earnings Call Presentation

August 11, 2023 | msn.com

Credit Suisse Reiterates Verve Therapeutics (VERV) Neutral Recommendation

August 11, 2023 | finance.yahoo.com

Investors in Verve Therapeutics (NASDAQ:VERV) have unfortunately lost 47% over the last year

August 11, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Third Harmonic Bio, Inc. (THRD) and Verve Therapeutics (VERV)

August 10, 2023 | msn.com

Verve Therapeutics GAAP EPS of -$0.87 beats by $0.05, revenue of $2.09M beats by $1.42M

August 10, 2023 | finance.yahoo.com

Verve Therapeutics Highlights Recent Company Progress and Reports Second Quarter 2023 Financial Results

August 10, 2023 | finance.yahoo.com

Verve Therapeutics (VERV) Reports Q2 Loss, Tops Revenue Estimates

August 3, 2023 | finance.yahoo.com

Verve Therapeutics to Present at the Canaccord 43rd Annual Growth Conference

July 25, 2023 | finance.yahoo.com

How Much Upside is Left in Verve Therapeutics (VERV)? Wall Street Analysts Think 93.5%

July 4, 2023 | bizjournals.com

How local researchers are turning Philadelphia into a hotspot for gene editing

See More Headlines

Receive VERV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verve Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VERV Company Calendar

Last Earnings: 8/10/2023
Today: 10/01/2023
Next Earnings (Estimated): 11/06/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:VERV
CUSIP: N/A
CIK: 1840574
Web: vervetx.com
Phone: 617-603-0070
Fax: N/A
Employees: 204
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $30.83
High Stock Price Forecast: $55.00
Low Stock Price Forecast: $13.00
Forecasted Upside/Downside: +132.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.17)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-157,390,000.00
Net Margins: -3,534.98%
Pretax Margin: -3,530.78%
Return on Equity: -37.08%
Return on Assets: -29.85%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 14.32
Quick Ratio: 14.32

Sales & Book Value

Annual Sales: $1.94 million
Price / Sales: 435.53
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $8.94 per share
Price / Book: 1.48

Miscellaneous

Outstanding Shares: 63,720,000
Free Float: 50,085,000
Market Cap: $844.93 million
Optionable: Not Optionable
Beta: 1.70

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Burt A. Adelman M.D. (Age 71)
Co-Founder & Independent Chairman
Comp: $87.55k

Dr. Sekar Kathiresan M.D. (Age 51)
Co-Founder, CEO & Director
Comp: $899.55k

Mr. Andrew D. Ashe J.D. (Age 56)
Pres, COO & Gen. Counsel
Comp: $703.85k

Dr. Andrew Bellinger M.D. (Age 45)
Ph.D., Chief Scientific Officer & Chief Medical Officer
Comp: $703.85k

Dr. Kiran Musunuru M.D.
M.P.H., Ph.D., Co-Founder & Sr. Scientific Advisor

Dr. J. Keith Joung M.D.
Ph.D., Co-Founder

Dr. Anthony Philippakis M.D.
Ph.D., Co-Founder & Scientific Advisory Board Member

Dr. Barry S. Ticho FACC (Age 62)
M.D., Ph.D., Co-Founder

Mr. Issi Rozen M.B.A.
Co-Founder & Strategic Advisor

Ms. Allison Dorval (Age 47)
CFO & Principal Accounting Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VERV Stock - Frequently Asked Questions

Should I buy or sell Verve Therapeutics stock right now?: 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Verve Therapeutics in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VERV shares.
View VERV analyst ratings or view top-rated stocks.
What is Verve Therapeutics' stock price forecast for 2023?: 8 brokers have issued 1 year price objectives for Verve Therapeutics' shares. Their VERV share price forecasts range from $13.00 to $55.00. On average, they predict the company's share price to reach $30.83 in the next twelve months. This suggests a possible upside of 132.5% from the stock's current price.
View analysts price targets for VERV or view top-rated stocks among Wall Street analysts.
How have VERV shares performed in 2023?: Verve Therapeutics' stock was trading at $19.35 at the beginning of the year. Since then, VERV shares have decreased by 31.5% and is now trading at $13.26.
View the best growth stocks for 2023 here.
When is Verve Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our VERV earnings forecast.
How were Verve Therapeutics' earnings last quarter?: Verve Therapeutics, Inc. (NASDAQ:VERV) released its quarterly earnings results on Thursday, August, 10th. The company reported ($0.87) earnings per share for the quarter, beating analysts' consensus estimates of ($0.90) by $0.03. The firm earned $2.10 million during the quarter, compared to analysts' expectations of $0.67 million. Verve Therapeutics had a negative trailing twelve-month return on equity of 37.08% and a negative net margin of 3,534.98%. The business's revenue for the quarter was up 2000.0% compared to the same quarter last year.
What ETFs hold Verve Therapeutics' stock?: ETFs with the largest weight of Verve Therapeutics (NASDAQ:VERV) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), ARK Genomic Revolution ETF (ARKG), Direxion Moonshot Innovators ETF (MOON), WisdomTree BioRevolution Fund (WDNA), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Global X Genomics & Biotechnology ETF (GNOM) and ARK Innovation ETF (ARKK).iShares Micro-Cap ETF (IWC).

When did Verve Therapeutics IPO?: (VERV) raised $201 million in an initial public offering (IPO) on Thursday, June 17th 2021. The company issued 11,800,000 shares at $16.00-$18.00 per share. J.P. Morgan, Jefferies, Guggenheim Securities and William Blair acted as the underwriters for the IPO.
What is Verve Therapeutics' stock symbol?: Verve Therapeutics trades on the NASDAQ under the ticker symbol "VERV."
How do I buy shares of Verve Therapeutics?: Shares of VERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Verve Therapeutics' stock price today?: One share of VERV stock can currently be purchased for approximately $13.26.
How much money does Verve Therapeutics make?: Verve Therapeutics (NASDAQ:VERV) has a market capitalization of $844.93 million and generates $1.94 million in revenue each year. The company earns $-157,390,000.00 in net income (profit) each year or ($3.17) on an earnings per share basis.
How many employees does Verve Therapeutics have?: The company employs 204 workers across the globe.
How can I contact Verve Therapeutics?: The official website for the company is vervetx.com. The company can be reached via phone at 617-603-0070 or via email at ir@vervetx.com.

This page (NASDAQ:VERV) was last updated on 10/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial